What are the specific reimbursement conditions for Belumosudil tablets and how to apply?

Belumosudil mesylate tablets (Belumosudil) have been included in medical insurance in China and have corresponding reimbursement conditions. According to the medical insurance policy, Besudil tablets are suitable for the treatment of patients with chronic graft-versus-host disease (GVHD) aged 12 years and above, especially those who cannot be effectively controlled by traditional treatments such as glucocorticoids or other systemic treatments. Besudil provides new treatment hope for these patients, who often face severe symptoms of an overreactive immune system, including organ damage and reduced quality of life.

Specific reimbursement conditions usually vary according to different regions and medical insurance policies, but in general, patients must meet the following conditions: First, the patient must be a patient who has been diagnosed with chronic graft-versus-host disease and be over 12 years old; secondly, the patient must be those who have an inadequate response to glucocorticoid treatment or other immunosuppressive treatments (such as cyclosporine, tacrolimus, etc.). In short, only those patients who have failed conventional treatments are eligible for treatment with besudil, and the drug is included in the treatment regimen as a second- or third-line treatment.

The process of applying for reimbursement usually requires patients to provide relevant medical diagnosis certificates, including medical records, treatment records, and doctors’ opinions. When submitting a medical insurance application, patients need to provide relevant information to the local medical insurance department to prove that they meet the conditions for medical insurance reimbursement. For specific operations, patients can consult with the medical insurance department or social medical insurance department of their hospital to learn about the specific application process and required documents. As the patient's information is submitted, the medical insurance department will review the application. Usually, after the review is passed, the patient can enjoy reimbursement benefits.

Besudil is relatively expensive, with a single box selling for about 10,000 to 20,000 yuan, so the coverage of medical insurance reimbursement will undoubtedly reduce the financial burden on patients. However, the specific reimbursement ratio and payment method still need to be determined according to local medical insurance policies and specific operating rules.

Reference materials:https://go.drugbank.com/drugs/DB16703